Navidea Biopharmaceuticals, Inc. | Ekinops
<div>Navidea Biopharmaceuticals, Inc. (OTC: NAVB), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced disappointing results of an exploratory analysis conducted on the company’s pivotal NAV3-33 clinical trial. Dr. Michael Blue, Navidea’s Chief Medical Officer, said "Results are not indicative of a commercially viable product.”<br> <br> Ekinops (Euronext Paris: EKI) (ISIN: FR0011466069), a leading supplier of optical transport and enterprise connectivity solutions for telecom operators and enterprises, today announced that Orange Business has chosen Ekinops …
इस घटना को अभी तक प्राधिकृत नहीं किया गया है
इस घटना को एआई के साथ ट्रॉइन करने के लिए STT.ai का इस्तेमाल करें. वक्ता के साथ यथार्थ पाठ प्राप्त करें, समय का पता लगाएँ, समय चिह्न, और अनेक फ़ॉर्मेटों में निर्यात करें.